fda warning letters glp-1 compounded september 2025 Fda Warning Letters Glp- 1 Compounded September 2025 There's lots going on this month at FDA FDA Achieves Year 1 Goals – FDA issues 30 warning letters

But if the field is to move forward, future trials will need to rethink both strategy and patient selection : Target the right patients : Are those with metabolic risk factors , diabetes or prediabetes, obesity, hypertension, more likely to benefit

Compounded drug products are not FDA-approved.Required Actions: Within 15 days, the company must respond in writing to the Office of Compounding Quality and Compliance (OCQC) with a description of how the company has addressed the violations, including removal of misleading language

This study is interesting in the synergistic effects, but people need to understand it was entirely retrospective and based on chart review, Uzmann says

doi: 10.1038/nsmb.2332 139 ShangGZhangCChenZJBaiX-CZhangX